English 日本語

Use case

USE CASE

Achievements

Epistra Accelerate has achieved results in a wide range of fields.

Pioneering the future of cell culture with “CellTune”
Pioneering the future of cell culture with “CellTune”

​Pioneering the future of cell culture with “CellTune” summary On September 4, 2024, Shi...

Searching for cell recipes for regenerative medicine using AI. Achieving efficiency equal to or greater than that of an expert.
Searching for cell recipes for regenerative medicine using AI. Achieving efficiency equal to or greater than that of an expert.

Searching for cell recipes for regenerative medicine using AI. Achieving efficiency equal to or grea...

Reducing R&D from Two Years to a Few Weeks: Discovering Conditions for High-Yield Structural Protein Production with AI
Reducing R&D from Two Years to a Few Weeks: Discovering Conditions for High-Yield Structural Protein Production with AI

Reducing R&D from Two Years to a Few Weeks: Discovering Conditions for High-Yield Structural Pro...

previous arrow
next arrow

We have received positive feedback from actual users.

Latest

最新記事

If you’re interested in learning more about our work or past cases, please don’t hesitate to contact us.

OTHER CASES

Track Record Across the Life Sciences Industry

We have a strong track record of delivering results across a range of life sciences domains.
Here are some of the measurable impacts we’ve made:

Productivity
Improvement

18

cases

Functionality
Quality Gain

11

cases

Raw Material
Cost Reduction

15

cases

Shorter R&D
Timelines

16

cases

Media Development for Antibody Drug Manufacturing

Using our AI-driven optimization engine Epistra Accelerate, integrated into the media optimization support software CellTune, we improved the composition of feed media for antibody production. As a result, we discovered a composition that increased antibody yield by approximately 40% compared to the baseline.

Optimization of Novel Assay Conditions

We conducted assay optimization for drug screening. Conditions discovered by Epistra Accelerate outperformed both the pre-optimization baseline (by 46%) and those found by human researchers (by 12%). In addition, AI-driven optimization completed in 2.5 months—reducing the R&D period by 44% compared to human-led efforts (4.5 months).

Performance Improvement in Cell Storage Reagents

We developed a high-performance cryopreservation reagent for cell therapy applications. Compared to commercially available alternatives, our optimized formulation increased cell recovery yield by 133% and enhanced cell functionality by 40%. It also demonstrated strong robustness to temperature and concentration variations while avoiding existing IP constraints.

Reduction in Media Costs

Media costs for pharmaceutical manufacturing can be significant. By maintaining comparable performance while minimizing raw material cost, we reduced total media costs by 70%—resulting in estimated annual savings of over 400 million JPY.

Animal-Origin-Free Media Development

Using Epistra Accelerate, we optimized MSC culture media to achieve higher proliferative performance while reducing raw material costs. All developed media are Animal-Origin-Free (AOF), containing no animal- or human-derived components.

PAST RESULTS

Antibody Drugs
Cell Preservation Reagents
Chemically Defined Media
Regenerative Medicine
Bio-manufacturing
Vaccine Production
Agricultural Breeding
Assay Development